Testing linperlisib plus CHOP for untreated peripheral T-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests linperlisib (a medicine that targets a cell-growth pathway) together with CHOP chemotherapy in people with peripheral T-cell lymphoma that has not been treated before. It may help shrink the lymphoma and control the disease by combining two approaches.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of peripheral T-cell lymphoma (PTCL), including specific subtypes such as PTCL NOS, AITL, or others.
- You must not have received any anti-cancer treatment for your lymphoma yet.
- Your scans must show at least one measurable lymphoma spot on PET-CT (FDG-uptake higher than the liver) and you must have adequate lesion size to measure.
- You must be age 18 or older, able to carry out daily activities fairly well (ECOG 0–2), and expected to live more than 3 months.
- Your heart, lung, liver, kidneys, and bone marrow function must be adequate based on blood tests and other checks (and you must not have certain severe/uncontrolled conditions).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding the targeted drug linperlisib to standard chemotherapy (CHOP) can help adults with certain types of peripheral T-cell lymphoma that haven't been treated yet. It aims to see if the combination works better than CHOP alone.
This trial is testing a combination of two targeted drugs (linperlisib and an EZH2 inhibitor) for people whose peripheral T-cell lymphoma has come back or not responded to previous treatment. The goal is to see if this new combination can help shrink tumors and slow the disease.
This trial tests two pills—linperlisib and chidamide—for people with a type of lymphoma called PTCL. The combination might work better together than either alone.
This trial tests a new drug called golidocitinib added to standard chemotherapy (CHOP) for people newly diagnosed with certain types of T-cell lymphoma. It aims to see if the combination works better than CHOP alone.
This trial tests a combination therapy with tazemetostat for people whose peripheral T-cell lymphoma has come back or hasn't responded to previous treatment. The goal is to see if this drug combination can help shrink tumors or slow the disease.
This Phase 2 trial compares two chemotherapy approaches—adding lenalidomide to CHOP versus CHOP alone—for people with untreated peripheral T-cell lymphoma (PTCL). The goal is to see if the added medicine improves response and safety.
Hear when a new Peripheral T Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.